SIRT1 mediates the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARα/FoxO1 signaling pathway

Zhang,Weiyan; Sun,Yue; Liu,Wei; Dong,Jinling; Chen,Jinglong

doi:10.3892/ijmm.2019.4059

SIRT1 mediates the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARα/FoxO1 signaling pathway

Authors:
- Weiyan Zhang
- Yue Sun
- Wei Liu
- Jinling Dong
- Jinglong Chen
View Affiliations

Affiliations: Department of Infectious Disease, Huaxin Hospital, The First Hospital of Tsinghua University, Beijing 100016, P.R. China, Department of Infectious Disease, First People's Hospital Affiliated to Huzhou University Medical College, Huzhou, Zhejiang 313000, P.R. China, Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P.R. China
Published online on: January 10, 2019 https://doi.org/10.3892/ijmm.2019.4059
Pages: 1271-1280
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic fatty liver disease (NAFLD) is the consequence of insulin resistance, fatty acid accumulation, oxidative stress and lipotoxicity. The present study aimed to elucidate the effect of Quaking 5 (QKI 5) as mediated by Sirtuin 1 (SIRT1) on triglyceride (TG) synthesis in the liver of an NAFLD mouse model. A high‑fat diet‑induced NAFLD model was established in mice, and mouse hepatocytes were isolated to characterize the effects of QKI 5 mediated by SIRT1 on TG synthesis in the liver. Body weight and liver wet weight were recorded. In addition, serum levels of total cholesterol, TG, alanine aminotransferase and aspartate aminotransferase were assessed using an automatic biochemistry analyzer. Hematoxylin and eosin staining was performed to observe the histological morphological alterations of the liver tissues. The concentration of SIRT1 in the serum was also detected. The NAFLD activity score (NAS) was used to evaluate disease severity. The synthesis of TGs in cells or tissues was determined, and the protein levels of SIRT1, QKI 5, peroxisome proliferator‑activated receptor (PPAR)α and Forkhead box protein O1 (FoxO1) were examined. The expression levels of SIRT1 or QKI 5, and the acetylation level of QKI 5 were decreased in the mouse model of NAFLD. QKI 5 was deacetylated by SIRT1, which contributed in suppressing the progression of NAFLD in the mice, and inhibiting TG synthesis in vivo and in vitro via the PPARα/FoxO1 signaling pathway. Taken together, the results of the present study demonstrated that SIRT1 deacetylated QKI 5, an RNA‑binding protein significantly affecting the synthesis of TG in the liver of the NAFLD mouse model. Furthermore, it activated transcription factor FOXO1 through post‑transcriptional regulation of the expression of PPARα and further inhibited the synthesis of TGs, thereby restraining the progression of NAFLD.

View Figures

View References

1	Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, Yun KE, Shin H and Ryu S: Non-heavy drinking and worsening of non-invasive fibrosis markers in nonalcoholic fatty liver disease: A cohort study. Hepatology. Jul 17–2018.Epub ahead of print.
2	Wang J, Yang W, Chen Z, Chen J, Meng Y, Feng B, Sun L, Dou L, Li J, Cui Q and Yang J: Long noncoding RNA lncSHGL recruits hnRNPA1 to suppress hepatic gluconeogenesis and lipogenesis. Diabetes. 67:581–593. 2018. View Article : Google Scholar : PubMed/NCBI
3	Jeong HS, Kim KH, Lee IS, Park JY, Kim Y, Kim KS and Jang HJ: Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice. Biomed Pharmacother. 88:625–634. 2017. View Article : Google Scholar : PubMed/NCBI
4	Tarantino G, Saldalamacchia G, Conca P and Arena A: Non-alcoholic fatty liver disease: Further expression of the metabolic syndrome. J Gastroenterol Hepatol. 22:293–303. 2007. View Article : Google Scholar : PubMed/NCBI
5	Affo S, Yu LX and Schwabe RF: The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 12:153–186. 2017. View Article : Google Scholar :
6	Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, et al: Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 69:896–904. 2018. View Article : Google Scholar : PubMed/NCBI
7	Buzzetti E, Pinzani M and Tsochatzis EA: The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 65:1038–1048. 2016. View Article : Google Scholar : PubMed/NCBI
8	Nassir F and Ibdah JA: Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol. 22:10084–10092. 2016. View Article : Google Scholar : PubMed/NCBI
9	Pillman KA, Phillips CA, Roslan S, Toubia J, Dredge BK, Bert AG, Lumb R, Neumann DP, Li X, Conn SJ, et al: miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking. EMBO J. 37:pii. e990162018. View Article : Google Scholar : PubMed/NCBI
10	Larocque D, Galarneau A, Liu HN, Scott M, Almazan G and Richard S: Protection of p27(Kip1) mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation. Nat Neurosci. 8:27–33. 2005. View Article : Google Scholar
11	Zhao L, Ku L, Chen Y, Xia M, LoPresti P and Feng Y: QKI binds MAP1B mRNA and enhances MAP1B expression during oligodendrocyte development. Mol Biol Cell. 17:4179–4186. 2006. View Article : Google Scholar : PubMed/NCBI
12	Saccomanno L, Loushin C, Jan E, Punkay E, Artzt K and Goodwin EB: The STAR protein QKI-6 is a translational repressor. Proc Natl Acad Sci USA. 96:12605–12610. 1999. View Article : Google Scholar : PubMed/NCBI
13	de Bruin RG, Shiue L, Prins J, de Boer HC, Singh A, Fagg WS, van Gils JM, Duijs JM, Katzman S, Kraaijeveld AO, et al: Quaking promotes monocyte differentiation into pro-atherogenic macrophages by controlling pre-mRNA splicing and gene expression. Nat Commun. 7:108462016. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Vogel G, Yu Z and Richard S: The QKI-5 and QKI-6 RNA binding proteins regulate the expression of microRNA 7 in glial cells. Mol Cell Biol. 33:1233–1243. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wang F, Song W, Zhao H, Ma Y, Li Y, Zhai D, Pi J, Si Y, Xu J, Dong L, et al: The RNA-binding protein QKI5 regulates primary miR-124-1 processing via a distal RNA motif during erythropoiesis. Cell Res. 27:416–439. 2017. View Article : Google Scholar : PubMed/NCBI
16	Hall MP, Nagel RJ, Fagg WS, Shiue L, Cline MS, Perriman RJ, Donohue JP and Ares M Jr: Quaking and PTB control overlapping splicing regulatory networks during muscle cell differentiation. RNA. 19:627–638. 2013. View Article : Google Scholar : PubMed/NCBI
17	van der Veer EP, de Bruin RG, Kraaijeveld AO, de Vries MR, Bot I, Pera T, Segers FM, Trompet S, van Gils JM, Roeten MK, et al: Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ Res. 113:1065–1075. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zong FY, Fu X, Wei WJ, Luo YG, Heiner M, Cao LJ, Fang Z, Fang R, Lu D, Ji H and Hui J: The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet. 10:e10042892014. View Article : Google Scholar : PubMed/NCBI
19	Fagg WS, Liu N, Fair JH, Shiue L, Katzman S, Donohue JP and Ares M Jr: Autogenous cross-regulation of Quaking mRNA processing and translation balances Quaking functions in splicing and translation. Genes Dev. 31:1894–1909. 2017. View Article : Google Scholar : PubMed/NCBI
20	Hayakawa-Yano Y, Suyama S, Nogami M, Yugami M, Koya I, Furukawa T, Zhou L, Abe M, Sakimura K, Takebayashi H, et al: An RNA-binding protein, Qki5, regulates embryonic neural stem cells through pre-mRNA processing in cell adhesion signaling. Genes Dev. 31:1910–1925. 2017. View Article : Google Scholar : PubMed/NCBI
21	Sonnemann J, Kahl M, Siranjeevi PM, Blumrich A, Blümel L, Becker S, Wittig S, Winkler R, Krämer OH and Beck JF: Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: Resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity. J Cancer Res Clin Oncol. 142:17–26. 2016. View Article : Google Scholar
22	Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, Beilfuss A, Schmitt J, Hannivoort RA, Kilicarslan A, et al: Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology. 57:1394–1406. 2013. View Article : Google Scholar : PubMed/NCBI
23	Biel TG, Lee S, Flores-Toro JA, Dean JW, Go KL, Lee MH, Law BK, Law ME, Dunn WA Jr, Zendejas I, et al: Sirtuin 1 suppresses mitochondrial dysfunction of ischemic mouse livers in a mitofusin 2-dependent manner. Cell Death Differ. 23:279–290. 2016. View Article : Google Scholar :
24	Kawano Y and Cohen DE: Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 48:434–441. 2013. View Article : Google Scholar : PubMed/NCBI
25	Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD and Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 115:1343–1351. 2005. View Article : Google Scholar : PubMed/NCBI
26	Wu T, Liu YH, Fu YC, Liu XM and Zhou XH: Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients. Ann Clin Lab Sci. 44:410–418. 2014.PubMed/NCBI
27	Bruce KD, Szczepankiewicz D, Sihota KK, Ravindraanandan M, Thomas H, Lillycrop KA, Burdge GC, Hanson MA, Byrne CD and Cagampang FR: Altered cellular redox status, sirtuin abundance and clock gene expression in a mouse model of developmentally primed NASH. Biochim Biophys Acta. 1861:584–593. 2016. View Article : Google Scholar : PubMed/NCBI
28	Geng C, Zhang Y, Gao Y, Tao W, Zhang H, Liu X, Fang F and Chang Y: Mst1 regulates hepatic lipid metabolism by inhibiting Sirt1 ubiquitination in mice. Biochem Biophys Res Commun. 471:444–449. 2016. View Article : Google Scholar : PubMed/NCBI
29	Colak Y, Yesil A, Mutlu HH, Caklili OT, Ulasoglu C, Senates E, Takir M, Kostek O, Yilmaz Y, Yilmaz Enc F, et al: A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. J Gastrointestin Liver Dis. 23:311–319. 2014.PubMed/NCBI
30	Colak Y, Ozturk O, Senates E, Tuncer I, Yorulmaz E, Adali G, Doganay L and Enc FY: SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit. 17:HY5–HY9. 2011. View Article : Google Scholar : PubMed/NCBI
31	Tobita T, Guzman-Lepe J, Takeishi K, Nakao T, Wang Y, Meng F, Deng CX, Collin de l'Hortet A and Soto-Gutierrez A: SIRT1 disruption in human fetal hepatocytes leads to increased accumulation of glucose and lipids. PLoS One. 11:e01493442016. View Article : Google Scholar : PubMed/NCBI
32	Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X and Li X: Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9:327–338. 2009. View Article : Google Scholar : PubMed/NCBI
33	Kim KE, Kim H, Heo RW, Shin HJ, Yi CO, Lee DH, Kim HJ, Kang SS, Cho GJ and Choi WS: Myeloid-specific SIRT1 deletion aggravates hepatic inflammation and steatosis in high-fat diet-fed mice. Korean J Physiol Pharmacol. 19:451–460. 2015. View Article : Google Scholar : PubMed/NCBI